Saturday - May 17, 2025
LEHI, Utah / Feb 22, 2024 / Business Wire / Owlet, Inc. (“Owlet”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that it will participate in the 44th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts. Kurt Workman, Owlet’s Co-Founder and Chief Executive Officer, and Kate Scolnick, Chief Financial Officer, are scheduled to engage in a fireside chat on Tuesday, March 5, 2024, at 2:50 p.m. Eastern Time.
A link to the live webcast of the fireside chat will be available on the Owlet Investor Relations website, investors.owletcare.com. A replay of the webcast will also be available on Owlet’s Investor Relations website.
About Owlet, Inc.
Owlet was founded by a team of parents in 2012. Owlet’s mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Owlet’s digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. Owlet believes that every parent deserves peace of mind and the opportunity to feel their well-rested best. Owlet also believes that every child deserves to live a long, happy, and healthy life, and is working to develop products to help further that belief. To learn more, visit www.owletcare.com.
Last Trade: | US$5.27 |
Daily Change: | -0.07 -1.31 |
Daily Volume: | 13,735 |
Market Cap: | US$84.530M |
May 08, 2025 March 04, 2025 January 28, 2025 September 13, 2024 September 11, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load